Search Media Items

Read the story of NCI-funded scientist Olivera Finn whose research led to the first clinical trial of a prevention vaccine for people at high risk for cancer.

Learn how Sue Wharfe benefitted from taking part in a clinical trial of exercise and nutrition for breast cancer survivors that was supported by NCI funding.

Approximately 70 percent of women diagnosed with ovarian cancer will die from the disease. Read about the NCI-funded combination drug trial that has successfully treated Betsy Brauser's recurrent cancer.

Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.

Cancer cells can develop resistance to drugs that were previously effective. This Cancer Moonshot initiative aims to increase understanding of how this resistance develops, and to use biomarkers to predict who will develop it, and ways to counteract it to improve patient care and survival.

This Cancer Moonshot initiative will engage patients to contribute their tumor profile data to expand knowledge about what therapies work, in whom, and in which types of cancer. A patient’s genomic data may guide treatment decisions.

This initiative aims to develop, test, and adopt proven cancer prevention and early detection approaches to reduce cancer risk and cancer health disparities in all populations.

While standard biological methods such as two-dimensional, in vitro cell culture and in vivo animal models are useful to examine certain biological questions, the complexity of cancer requires a continuum of model systems. This collaborative study will create a foundation for tumor tissue engineering by employing multiple innovative methodologies to first characterize and then build biomimetic models of the extracellular matrix (ECM) in the tumor microenvironment. The ECM is a key element in biomimicry, and particularly important to consider in the context of cancer, where the composition and architecture of the ECM change drastically with disease progression.

Read how melanoma survivor T.J. Sharpe’s experience on two clinical trials highlights the need for biomarkers to predict benefit from immunotherapy.

Carcinoma of unknown primary (CUP), treatment can include surgery, radiation therapy, chemotherapy, or hormone therapy. Get detailed information about the diagnosis and treatment of CUP in this expert-reviewed summary.